{"transactions":[{"id":4637798,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-08T20:07:04.000Z","date":"2026-10-07","kind":"sale","planned":true,"acquired":false,"shares":1147,"price":30.66,"value":35167.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":452245,"source":{"system":"sec-edgar","filing":"0001193125-26-417919","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526417919/ownership.xml","form_type":"4"}},{"id":4637797,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-08T20:07:04.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":3375,"price":32.0314,"value":108105.975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.65 to $32.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":453392,"source":{"system":"sec-edgar","filing":"0001193125-26-417919","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526417919/ownership.xml","form_type":"4"}},{"id":4626010,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-24T20:05:09.000Z","date":"2026-09-23","kind":"sale","planned":true,"acquired":false,"shares":43,"price":41.05,"value":1765.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."}],"balance_after":456767,"source":{"system":"sec-edgar","filing":"0001193125-26-401017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526401017/ownership.xml","form_type":"4"}},{"id":4626009,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-24T20:05:09.000Z","date":"2026-09-23","kind":"sale","planned":true,"acquired":false,"shares":215,"price":39.8602,"value":8569.943,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.57 to $40.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":456810,"source":{"system":"sec-edgar","filing":"0001193125-26-401017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526401017/ownership.xml","form_type":"4"}},{"id":4626008,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-24T20:05:09.000Z","date":"2026-09-23","kind":"sale","planned":true,"acquired":false,"shares":1952,"price":39.0523,"value":76230.0896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.54 to $39.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":457025,"source":{"system":"sec-edgar","filing":"0001193125-26-401017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526401017/ownership.xml","form_type":"4"}},{"id":4613250,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-09T20:05:05.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":1069,"price":46.0147,"value":49189.7143,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.95 to $46.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":458977,"source":{"system":"sec-edgar","filing":"0001193125-26-386436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526386436/ownership.xml","form_type":"4"}},{"id":4613249,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-09T20:05:05.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":7141,"price":45.555,"value":325308.255,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.94 to $45.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":460046,"source":{"system":"sec-edgar","filing":"0001193125-26-386436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526386436/ownership.xml","form_type":"4"}},{"id":675225,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-26T20:05:03.000Z","date":"2026-08-25","kind":"sale","planned":true,"acquired":false,"shares":18921,"price":49.5723,"value":937957.4883,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.03 to $50.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":467187,"source":{"system":"sec-edgar","filing":"0001193125-26-368285","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526368285/ownership.xml","form_type":"4"}},{"id":689466,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:35:43.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":5794,"price":48.6229,"value":281721.0826,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.45 to $48.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":486108,"source":{"system":"sec-edgar","filing":"0001193125-26-346995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526346995/ownership.xml","form_type":"4"}},{"id":689465,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:35:43.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":19500,"price":48.0434,"value":936846.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.45 to $48.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":491902,"source":{"system":"sec-edgar","filing":"0001193125-26-346995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526346995/ownership.xml","form_type":"4"}},{"id":689464,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:35:43.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":3664,"price":46.8988,"value":171837.2032,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.32 to $47.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":511402,"source":{"system":"sec-edgar","filing":"0001193125-26-346995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526346995/ownership.xml","form_type":"4"}},{"id":689463,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:35:43.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":8370,"price":46.7479,"value":391279.923,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.38 to $47.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":515066,"source":{"system":"sec-edgar","filing":"0001193125-26-346995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526346995/ownership.xml","form_type":"4"}},{"id":689462,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:35:43.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":14171,"price":45.9736,"value":651491.8856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.37 to $46.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":523436,"source":{"system":"sec-edgar","filing":"0001193125-26-346995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526346995/ownership.xml","form_type":"4"}},{"id":701572,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-29T20:05:02.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":7,"price":42.735,"value":299.145,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."}],"balance_after":537607,"source":{"system":"sec-edgar","filing":"0001193125-26-323637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526323637/ownership.xml","form_type":"4"}},{"id":701571,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-29T20:05:02.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":2203,"price":42.107,"value":92761.721,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.66 to $42.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":537614,"source":{"system":"sec-edgar","filing":"0001193125-26-323637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526323637/ownership.xml","form_type":"4"}},{"id":709179,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-15T20:15:03.000Z","date":"2026-07-14","kind":"sale","planned":true,"acquired":false,"shares":2729,"price":40.5724,"value":110722.0796,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.37 to $40.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":539817,"source":{"system":"sec-edgar","filing":"0001193125-26-304786","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526304786/ownership.xml","form_type":"4"}},{"id":709178,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-15T20:15:03.000Z","date":"2026-07-14","kind":"sale","planned":true,"acquired":false,"shares":5481,"price":39.7217,"value":217714.6377,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.36 to $40.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":542546,"source":{"system":"sec-edgar","filing":"0001193125-26-304786","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526304786/ownership.xml","form_type":"4"}},{"id":721541,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:05:03.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":876,"price":40.3375,"value":35335.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.26 to $40.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":548027,"source":{"system":"sec-edgar","filing":"0001193125-26-292519","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526292519/ownership.xml","form_type":"4"}},{"id":721540,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:05:03.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":7344,"price":39.7688,"value":292062.0672,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.25 to $40.225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":548903,"source":{"system":"sec-edgar","filing":"0001193125-26-292519","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526292519/ownership.xml","form_type":"4"}},{"id":785215,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-11T20:51:41.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1438,"price":177.62,"value":255417.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":2384,"source":{"system":"sec-edgar","filing":"0001100682-26-000062","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000110068226000062/form4.xml","form_type":"4"}},{"id":893711,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-20T00:06:29.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":2100,"price":29.7965,"value":62572.65,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.52 to $30.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":20729,"source":{"system":"sec-edgar","filing":"0001193125-26-059886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526059886/ownership.xml","form_type":"4"}},{"id":893710,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-20T00:06:29.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":2983,"price":29.0443,"value":86639.1469,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":22829,"source":{"system":"sec-edgar","filing":"0001193125-26-059886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526059886/ownership.xml","form_type":"4"}},{"id":893709,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-20T00:06:29.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":2281,"price":29.7983,"value":67969.9223,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.56 to $30.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":556247,"source":{"system":"sec-edgar","filing":"0001193125-26-059886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526059886/ownership.xml","form_type":"4"}},{"id":893708,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-20T00:06:29.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":3552,"price":29.0516,"value":103191.2832,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":558528,"source":{"system":"sec-edgar","filing":"0001193125-26-059886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526059886/ownership.xml","form_type":"4"}},{"id":919666,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:14:58.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":428000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":428000,"derivative":{"exercise_price":27.75,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":428000},"source":{"system":"sec-edgar","filing":"0001193125-26-037603","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526037603/ownership.xml","form_type":"4"}},{"id":933549,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-23T00:00:09.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":5083,"price":26.114,"value":132737.462,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.83 to $26.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":25812,"source":{"system":"sec-edgar","filing":"0001193125-26-019820","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526019820/ownership.xml","form_type":"4"}},{"id":933548,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-23T00:00:09.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":5833,"price":26.1158,"value":152333.4614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.83 to $26.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":562080,"source":{"system":"sec-edgar","filing":"0001193125-26-019820","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526019820/ownership.xml","form_type":"4"}},{"id":963342,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":515,"price":31.0396,"value":15985.394,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.75 to $31.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":30895,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":963341,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":2421,"price":30.0378,"value":72721.5138,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":31410,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":963340,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":2147,"price":28.8425,"value":61924.8475,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":33831,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":963339,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":600,"price":31.036,"value":18621.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.78 to $31.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":567913,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":963338,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":2792,"price":30.0365,"value":83861.908,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":568513,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":963337,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":2441,"price":28.8378,"value":70393.0698,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":571305,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":996109,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:27:41.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":2841,"price":25.437,"value":72266.517,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.23 to $25.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":35978,"source":{"system":"sec-edgar","filing":"0001193125-25-286218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525286218/ownership.xml","form_type":"4"}},{"id":996108,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:27:41.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":2242,"price":24.9107,"value":55849.7894,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.21 to $25.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":38819,"source":{"system":"sec-edgar","filing":"0001193125-25-286218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525286218/ownership.xml","form_type":"4"}},{"id":996107,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:27:41.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":3056,"price":25.4303,"value":77714.9968,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.22 to $25.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":573746,"source":{"system":"sec-edgar","filing":"0001193125-25-286218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525286218/ownership.xml","form_type":"4"}},{"id":996106,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:27:41.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":2777,"price":24.9246,"value":69215.6142,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.22 to $25.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":576802,"source":{"system":"sec-edgar","filing":"0001193125-25-286218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525286218/ownership.xml","form_type":"4"}},{"id":1017709,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-16T20:30:03.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":755,"price":26.1721,"value":19759.9355,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.08 to $26.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":41061,"source":{"system":"sec-edgar","filing":"0001193125-25-241472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525241472/ownership.xml","form_type":"4"}},{"id":1017708,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-16T20:30:03.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":4328,"price":25.746,"value":111428.688,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.07 to $26.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":41816,"source":{"system":"sec-edgar","filing":"0001193125-25-241472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525241472/ownership.xml","form_type":"4"}},{"id":1017707,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-16T20:30:03.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":1186,"price":26.1392,"value":31001.0912,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.06 to $26.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":579579,"source":{"system":"sec-edgar","filing":"0001193125-25-241472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525241472/ownership.xml","form_type":"4"}},{"id":1017706,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-16T20:30:03.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":4647,"price":25.724,"value":119539.428,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.06 to $26.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":580765,"source":{"system":"sec-edgar","filing":"0001193125-25-241472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525241472/ownership.xml","form_type":"4"}},{"id":1035722,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-19T20:05:05.000Z","date":"2025-09-17","kind":"sale","planned":true,"acquired":false,"shares":700,"price":27.0429,"value":18930.03,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.02 to $27.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":46144,"source":{"system":"sec-edgar","filing":"0001193125-25-209062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525209062/ownership.xml","form_type":"4"}},{"id":1035721,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-19T20:05:05.000Z","date":"2025-09-17","kind":"sale","planned":true,"acquired":false,"shares":34885,"price":26.3019,"value":917541.7815,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.78 to $26.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":46844,"source":{"system":"sec-edgar","filing":"0001193125-25-209062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525209062/ownership.xml","form_type":"4"}},{"id":1035720,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-19T20:05:05.000Z","date":"2025-09-17","kind":"sale","planned":true,"acquired":false,"shares":1400,"price":26.8745,"value":37624.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.74 to $27.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":585412,"source":{"system":"sec-edgar","filing":"0001193125-25-209062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525209062/ownership.xml","form_type":"4"}},{"id":1035719,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-19T20:05:05.000Z","date":"2025-09-17","kind":"sale","planned":true,"acquired":false,"shares":39435,"price":26.299,"value":1037101.065,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":586812,"source":{"system":"sec-edgar","filing":"0001193125-25-209062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525209062/ownership.xml","form_type":"4"}},{"id":1045640,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-08T21:37:14.000Z","date":"2025-09-04","kind":"sale","planned":true,"acquired":false,"shares":2354,"price":27.19,"value":64005.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."}],"balance_after":9039,"source":{"system":"sec-edgar","filing":"0001396814-25-000109","document":"wk-form4_1757367430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000109/wk-form4_1757367430.xml","form_type":"4"}},{"id":1111153,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:18:26.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date."}],"balance_after":11279,"derivative":{"exercise_price":24.34,"exercise_date":"2026-06-11","expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":11279},"source":{"system":"sec-edgar","filing":"0001396814-25-000086","document":"wk-form4_1749845900.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000086/wk-form4_1749845900.xml","form_type":"4"}},{"id":1111152,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:18:26.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."}],"balance_after":11393,"source":{"system":"sec-edgar","filing":"0001396814-25-000086","document":"wk-form4_1749845900.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000086/wk-form4_1749845900.xml","form_type":"4"}},{"id":1123403,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-04T20:45:04.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":2082,"price":135.04,"value":281153.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The stock options become exercisable upon the earlier of 6/2/2026 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":2082,"derivative":{"exercise_price":135.04,"exercise_date":"2026-06-02","expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":2082},"source":{"system":"sec-edgar","filing":"0001127602-25-016733","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760225016733/form4.xml","form_type":"4"}},{"id":1123402,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-04T20:45:04.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":946,"price":135.04,"value":127747.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 6/2/2026 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":946,"source":{"system":"sec-edgar","filing":"0001127602-25-016733","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760225016733/form4.xml","form_type":"4"}},{"id":1285299,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T22:30:04.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":428000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":428000,"derivative":{"exercise_price":16.6,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":428000},"source":{"system":"sec-edgar","filing":"0000950170-25-013751","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025013751/ownership.xml","form_type":"4"}},{"id":1480282,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-13T22:13:47.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":12179,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12179,"derivative":{"exercise_price":28.68,"exercise_date":"2025-06-12","expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":12179},"source":{"system":"sec-edgar","filing":"0001396814-24-000079","document":"wk-form4_1718316820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000079/wk-form4_1718316820.xml","form_type":"4"}},{"id":1480281,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T22:13:47.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":5230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest on June 12, 2025, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."}],"balance_after":5230,"source":{"system":"sec-edgar","filing":"0001396814-24-000079","document":"wk-form4_1718316820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000079/wk-form4_1718316820.xml","form_type":"4"}},{"id":1485274,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-10T23:39:36.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":530647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option shall vest and become exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":530647,"derivative":{"exercise_price":17,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":530647},"source":{"system":"sec-edgar","filing":"0000950170-24-071533","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071533/ownership.xml","form_type":"4"}},{"id":1761701,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-11T20:46:28.000Z","date":"2023-10-06","kind":"grant","planned":false,"acquired":true,"shares":30967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 36 equal successive monthly installments over the 36-month period following the date of grant, subject to the reporting person's continued service as a director."}],"balance_after":30967,"derivative":{"exercise_price":29.8,"expiration_date":"2033-10-06","underlying":"Common Stock","underlying_shares":30967},"source":{"system":"sec-edgar","filing":"0001396814-23-000070","document":"wk-form4_1697057179.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000070/wk-form4_1697057179.xml","form_type":"4"}},{"id":2026615,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Restricted Stock Units","published_at":"2023-02-08T20:29:19.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":29083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":29083,"derivative":{"underlying":"Common Stock","underlying_shares":29083},"source":{"system":"sec-edgar","filing":"0000899243-23-004363","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323004363/doc4.xml","form_type":"4"}},{"id":2026614,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-08T20:29:19.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":114445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":114445,"derivative":{"exercise_price":34.41,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":114445},"source":{"system":"sec-edgar","filing":"0000899243-23-004363","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323004363/doc4.xml","form_type":"4"}},{"id":2161335,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-12T16:24:19.000Z","date":"2022-09-08","kind":"exercise","acquired":false,"shares":19210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":365009,"derivative":{"exercise_price":13.17,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":19210},"source":{"system":"sec-edgar","filing":"0000899243-22-030798","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322030798/doc4.xml","form_type":"4"}},{"id":2161334,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-09-12T16:24:19.000Z","date":"2022-09-08","kind":"sale","acquired":false,"shares":19210,"price":32.5,"value":624325.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-030798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322030798/doc4.xml","form_type":"4"}},{"id":2161333,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-09-12T16:24:19.000Z","date":"2022-09-08","kind":"exercise","acquired":true,"shares":19210,"price":13.17,"value":252995.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."}],"balance_after":19210,"source":{"system":"sec-edgar","filing":"0000899243-22-030798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322030798/doc4.xml","form_type":"4"}},{"id":2175037,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T16:05:50.000Z","date":"2022-08-22","kind":"exercise","acquired":false,"shares":9605,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":384219,"derivative":{"exercise_price":13.17,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":9605},"source":{"system":"sec-edgar","filing":"0000899243-22-029606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322029606/doc4.xml","form_type":"4"}},{"id":2175036,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-08-24T16:05:50.000Z","date":"2022-08-22","kind":"sale","acquired":false,"shares":9605,"price":32.5,"value":312162.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-029606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322029606/doc4.xml","form_type":"4"}},{"id":2175035,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-08-24T16:05:50.000Z","date":"2022-08-22","kind":"exercise","acquired":true,"shares":9605,"price":13.17,"value":126497.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."}],"balance_after":9605,"source":{"system":"sec-edgar","filing":"0000899243-22-029606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322029606/doc4.xml","form_type":"4"}},{"id":2181934,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-17T16:15:13.000Z","date":"2022-08-15","kind":"exercise","acquired":false,"shares":9606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":393824,"derivative":{"exercise_price":13.17,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":9606},"source":{"system":"sec-edgar","filing":"0000899243-22-028978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322028978/doc4.xml","form_type":"4"}},{"id":2181933,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-08-17T16:15:13.000Z","date":"2022-08-15","kind":"sale","acquired":false,"shares":9606,"price":34.12,"value":327756.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322028978/doc4.xml","form_type":"4"}},{"id":2181932,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-08-17T16:15:13.000Z","date":"2022-08-15","kind":"exercise","acquired":true,"shares":9606,"price":13.17,"value":126511.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."}],"balance_after":9606,"source":{"system":"sec-edgar","filing":"0000899243-22-028978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322028978/doc4.xml","form_type":"4"}},{"id":2190981,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-09T20:59:18.000Z","date":"2022-08-08","kind":"exercise","acquired":false,"shares":19211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":403430,"derivative":{"exercise_price":13.17,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":19211},"source":{"system":"sec-edgar","filing":"0000899243-22-028178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322028178/doc4.xml","form_type":"4"}},{"id":2190980,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-09T20:59:18.000Z","date":"2022-08-05","kind":"exercise","acquired":false,"shares":38424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":422641,"derivative":{"exercise_price":13.17,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":38424},"source":{"system":"sec-edgar","filing":"0000899243-22-028178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322028178/doc4.xml","form_type":"4"}},{"id":2190979,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-08-09T20:59:18.000Z","date":"2022-08-08","kind":"sale","acquired":false,"shares":9605,"price":39.5,"value":379397.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322028178/doc4.xml","form_type":"4"}},{"id":2190978,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-08-09T20:59:18.000Z","date":"2022-08-08","kind":"sale","acquired":false,"shares":9606,"price":37.75,"value":362626.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."}],"balance_after":9605,"source":{"system":"sec-edgar","filing":"0000899243-22-028178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322028178/doc4.xml","form_type":"4"}},{"id":2190977,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-08-09T20:59:18.000Z","date":"2022-08-08","kind":"exercise","acquired":true,"shares":19211,"price":13.17,"value":253008.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."}],"balance_after":19211,"source":{"system":"sec-edgar","filing":"0000899243-22-028178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322028178/doc4.xml","form_type":"4"}},{"id":2190976,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-08-09T20:59:18.000Z","date":"2022-08-05","kind":"sale","acquired":false,"shares":38424,"price":32.5,"value":1248780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 - $32.51. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322028178/doc4.xml","form_type":"4"}},{"id":2190975,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-08-09T20:59:18.000Z","date":"2022-08-05","kind":"exercise","acquired":true,"shares":38424,"price":13.17,"value":506044.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person."}],"balance_after":38424,"source":{"system":"sec-edgar","filing":"0000899243-22-028178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322028178/doc4.xml","form_type":"4"}},{"id":2401916,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-11T18:46:35.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":120310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter."}],"balance_after":120310,"derivative":{"exercise_price":30.36,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":120310},"source":{"system":"sec-edgar","filing":"0000899243-22-005940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322005940/doc4.xml","form_type":"4"}},{"id":2683565,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T16:24:24.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":461065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":461065,"derivative":{"exercise_price":13.17,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":461065},"source":{"system":"sec-edgar","filing":"0000899243-21-021786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924321021786/doc4.xml","form_type":"4"}},{"id":4094567,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-19T16:25:44.000Z","date":"2018-01-17","kind":"grant","acquired":true,"shares":80971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares vest over a four-year period, at a rate of 25% on the first anniversary of the grant date, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares are fully vested on the fourth anniversary of the grant date."}],"balance_after":80971,"derivative":{"exercise_price":12.23,"expiration_date":"2028-01-17","underlying":"Common Stock","underlying_shares":80971},"source":{"system":"sec-edgar","filing":"0000899243-18-001522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924318001522/doc4.xml","form_type":"4"}}]}